Daily non-political popular news in brief.

Nonmedicinal treatment touted for preschoolers with ADHD

Researchers from Lehigh University and Lehigh Valley Hospital report their findings in the current issue of School Psychology Review, which is devoted to ADHD. Teachers also noted increases in early literacy skills. Goal of the study was to ease problems associated with the lifelong disorder before children enroll in elementary school.

Read more »

Keywords: nonmedicinal, treatment, touted, preschoolers, adhd, preschooler

« Previous | Next »

Similar news on "Nonmedicinal treatment touted for preschoolers with ADHD":

1. Preschoolers with ADHD improve with low doses of medication
   10-16-2006 · EurekAlert!
   The first long-term, large-scale study designed to determine the safety and effectiveness of treating preschoolers who have attention deficit/hyperactivity disorder with methylphenidate has found that overall, low doses of this medication are effective and safe. However, the study found that children this age are more sensitive than older children to the medication's side effects and therefore should be closely monitored.
   Similar news · Read more »
   
2. Popular ADHD drug safe and effective for pre-schoolers
   10-23-2006 · EurekAlert!
   A new study by researchers from the Johns Hopkins Children's Center and five other medical centers concludes that carefully measured, low doses of methylphenidate (Ritalin) are safe and effective for attention-deficit and hyperactivity disorder (ADHD) in preschoolers. Investigators warn, however, that three to five-year-olds appear more sensitive to the drug's side effects, which include irritability, insomnia and weight loss, than are older children with ADHD and require closer monitoring.
   Similar news · Read more »
   
3. Study raises new treatment possibilities for cognitive disorders
   05-01-2007 · EurekAlert!
   UC Irvine researchers have identified a new class of compounds that could be used for drugs to treat cognitive disorders that accompany schizophrenia, Alzheimer's disease and ADHD, according to an article published today in the online version of the Proceedings of the National Academy of Sciences.
   Similar news · Read more »
   
4. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
   09-03-2007 · EurekAlert!
   An estimated 8.7 percent of U.S. children age 8 to 15 meet diagnostic criteria for attention-deficit/hyperactivity disorder, but fewer than half receive treatment, according to a report in the September issue of Archives of Pediatrics and Adolescent Medicine, one of the JAMA/Archives journals.
   Similar news · Read more »
   
5. Lisdexamfetamine dimesylate in ADHD phase 3 data presented
   10-27-2006 · EurekAlert!
   Shire and New River Pharmaceuticals Inc. announce that their investigational ADHD treatment, lisdexamfetamine dimesylate, also known as NRP104 or LDX, yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 12 years who received six months of treatment in an open-label phase 3 study presented at a national meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
6. Mayo Clinic study indicates medication for ADHD may help student outcomes
   09-18-2007 · EurekAlert!
   In an 18-year-study on attention-deficit/hyperactivity disorder, Mayo Clinic researchers found that treatment with prescription stimulants is associated with improved long-term academic success of children with ADHD. The Mayo Clinic results are the first population-based data to show stimulant drug therapy helps improve long-term school outcomes.
   Similar news · Read more »
   
7. Study raises questions about diagnosis, medical treatment of ADHD
   01-22-2008 · EurekAlert!
   A new UCLA study shows that only about half of children diagnosed with attention-deficit hyperactivity disorder, or ADHD, exhibit the cognitive defects commonly associated with the condition and further, found that in populations where medication is rarely prescribed to treat ADHD, the prevalence and symptoms of the disorder are roughly equivalent to populations in which medication is widely used.
   Similar news · Read more »
   
8. Collaborative study to focus on research, education, treatment for children with ADHD
   11-06-2006 · UT Southwestern Medical Center
   UT Southwestern Medical Center, UT Dallas' Center for BrainHealth and Shelton School of Dallas will join forces to conduct an innovative three-year research study aimed at helping children with attention deficit hyperactivity disorder and their families.
   Similar news · Read more »
   
9. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
   05-23-2007 · EurekAlert!
   Shire plc announced positive results of four studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term and two long-term phase 3 studies, presented at the American Psychiatric Association annual meeting, demonstrated GXR significantly improved all core symptoms of ADHD in children aged 6 to 17 years. GXR is the first selective alpha-2A-adrenoceptor agonist tested in well-controlled studies as an ADHD treatment.
   Similar news · Read more »
   
10. 12-month study demonstrated tolerability and efficacy of Daytrana
    05-23-2007 · EurekAlert!
    Shire plc announced that Daytrana, the first and only non-oral medication approved for treatment of ADHD in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association annual meeting.
    Similar news · Read more »